Fala, L. (2015). Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits.
শিকাগো স্টাইলে সাইটেশনFala, Loretta. "Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients With Type 2 Diabetes." Am Health Drug Benefits 2015.
এমএলএ সাইটেশনFala, Loretta. "Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients With Type 2 Diabetes." Am Health Drug Benefits 2015.
সতর্কবাণী: সাইটেশন সবসময় 100% নির্ভুল হতে পারে না.